

# NGL Fine-Chem Limited

Regd. Office : 301, E - Square, Subhash Road, Vile Parle East, Mumbai 400057, Maharashtra, INDIA  
Tel.: (+91 22) 26636450 Fax : 26108030 Email : info@nglfinechem.com CIN : L24110MH1981PLC025884, Website : www.nglfinechem.com

July 31, 2019

To,  
Department of Corporate Service (DCS-CRD),  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001.

**Subject: Outcome of the Board Meeting Dated 31<sup>st</sup> July, 2019.**

Dear Sir,

**This is to inform you that the Second Meeting of the Board of Directors of NGL Fine-Chem Limited for the financial year 2019-2020 held at the registered office of the Company on Wednesday, July 31, 2019 at 4.30 p.m and concluded at 6.30 p.m approved the following:**

Approved Unaudited Standalone & Consolidated Financial Results for the quarter ended 30th June, 2019 pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulations.

We further enclose herewith the Limited Review Report on Standalone and Consolidated Financial Results issued by the Statutory Auditors of the Company. The aforesaid results are also being disseminated on Company's website at [www.nglfinechem.com](http://www.nglfinechem.com).

Kindly take the same on your record and acknowledge receipt of the same.

**Thanking You,**

Yours truly,

**FOR NGL FINE-CHEM LTD**



**Pallavi Pednekar**  
**Company Secretary/ Compliance Officer**  
**Membership No: A33498**



# MANEK & ASSOCIATES

CHARTERED ACCOUNTANTS

3, Shanti Kunj, 17, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

Off. # 2618 5110

# 2618 5137

Fax # 2618 4912

shailesh.manek@gmail.com

www.camaneek.com

## SHAILESH MANEK

B.Com.(Hons), Grad. C.W.A., F.C.A.

### Independent Auditor's Review Report

To,  
The Board of Directors,  
NGL Fine-Chem Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **M/s.NGL Fine-Chem Limited** ("the Parent") and its subsidiary **M/s.MacrotechPolychem Private Limited** (the Parent and its subsidiary together referred to as "the Group", and its share of the net profit/loss) after tax and total comprehensive income/loss of its associates and joint ventures for the quarter ended **30<sup>th</sup> June 2019** and for the period from **01<sup>st</sup> April 2019 to 30<sup>th</sup> June 2019** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended **June 2018** and the corresponding period from **1<sup>st</sup> April 2018 to 30<sup>th</sup> June 2018**, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.  
  
We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the result of M/s. MacrotechPolychem Private Limited, its wholly owned subsidiary.

# MANEK & ASSOCIATES

5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MANEK & ASSOCIATES  
Chartered Accountants  
Firm's Registration No.:126679W



MUMBAI  
DATED: 31<sup>st</sup> July, 2019

*SL Manek*

(SHAILESH MANEK)  
Proprietor

Membership Number:034925  
UDIN: 19034925AAAADX1533





# MANEK & ASSOCIATES

CHARTERED ACCOUNTANTS

3, Shanti Kunj, 17, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

Off. # 2618 5110  
# 2618 5137  
Fax # 2618 4912  
shailesh.manek@gmail.com  
www.camaneek.com

## SHAILESH MANEK

B.Com.(Hons), Grad. C.W.A., F.C.A.

Review report to.  
The Board of Directors,  
NGL Fine-Chem Limited...

We have reviewed the accompanying statement of unaudited financial results of M/s.NGL Fine-Chem Limited for the period ended **June 2019**.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MANEK & ASSOCIATES**  
Chartered Accountants  
Firm's Registration No.: 126679W



**MUMBAI**  
**DATED: 31<sup>st</sup> July, 2019**

  
**(SHAILESH MANEK)**  
Proprietor  
Membership Number: 034925  
UDIN: 19034925AAAADY4960



# NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road, Vile Parle ( East), Mumbai 400 057

CIN: L24110MH1981PLC025884


## UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2019

Rupees in lakhs

	Quarter ended			Year ended
	30.06.2019 (Unaudited)	31.03.2019 (Audited)	30.06.2018 (Unaudited)	
I	4,069.91	4,416.57	3,485.30	15,317.43
II	135.40	125.47	223.76	411.95
III	4,205.31	4,542.04	3,709.06	15,729.38
IV	Expenses :			
a)	1,594.89	1,492.53	1,623.57	6,390.32
b)	35.80	278.28	(151.47)	(126.65)
c)	586.81	570.45	481.39	2,116.49
d)	48.39	53.59	58.65	228.71
e)	186.76	187.51	157.03	630.02
f)	1,007.52	972.13	1,018.38	3,793.84
	3,460.17	3,554.49	3,187.55	12,972.73
V	745.14	987.55	521.51	2,756.65
VI	-	-	-	-
VII	745.14	987.55	521.51	2,756.65
VIII	Tax Expense			
a)	(217.50)	(251.64)	(180.00)	(780.00)
b)	-	-	-	-
c)	(8.04)	(26.41)	(8.42)	(21.88)
d)	519.60	667.62	498.24	2,012.68
IX	519.60	667.62	498.24	2,012.68
X	Other Comprehensive Income			
a)	(4.26)	(0.75)	(0.75)	(6.43)
b)	1.24	0.22	0.22	1.87
c)	(3.02)	(0.53)	(0.53)	(4.56)
XI	551.45	667.09	498.24	2,008.13
XII	308.90	308.90	308.90	308.90
XXIII	N.A	N.A	N.A	8,903.40
XIV	8.97	11.13	11.02	32.58
a)	8.97	11.13	11.02	32.58
b)	8.97	11.13	11.02	32.58

### Notes:

- The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Wednesday, 31st July, 2019. These results were subjected to Limited Review by the Statutory Auditors of the Company.
- The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
- Previous period figures have been regrouped/rearranged wherever necessary.
- Previous period figures have been regrouped/rearranged wherever necessary.

  
 Rahul Nachane  
 Managing Director  
 DIN 00223346

For and On behalf of Board of Directors

Rupees in lakhs

	Quarter ended			Year ended
	30.06.2019 (Unaudited)	31.03.2019 (Audited)	30.06.2018 (Unaudited)	
I	4,069.91	4,416.57	3,529.45	15,496.03
II	135.40	125.47	223.76	412.56
III	4,205.31	4,542.04	3,753.21	15,908.59
IV	Expenses :			
a)	1,594.89	1,492.53	1,623.57	6,409.11
b)	35.80	278.28	(151.47)	(126.65)
c)	586.81	570.45	488.99	2,150.45
d)	48.39	53.59	58.66	228.87
e)	186.76	187.51	157.03	656.39
f)	1,007.52	972.13	1,040.34	3,824.76
	3,460.17	3,554.49	3,217.12	13,142.93
V	745.14	987.55	536.09	2,765.66
VI	-	-	-	-
VII	745.14	987.55	536.09	2,765.66
VIII	Tax Expense			
a)	(217.50)	(251.64)	(180.00)	(781.73)
b)	-	-	-	0.09
c)	(8.04)	(26.41)	(8.42)	(21.88)
d)	519.60	667.62	496.72	2,019.32
IX	519.60	667.62	496.72	2,019.32
X	Other Comprehensive Income			
a)	(4.26)	(0.75)	23.11	(6.43)
b)	1.24	0.22	(6.73)	1.87
c)	(3.02)	(0.53)	16.38	(4.56)
XI	516.58	667.09	513.10	2,014.76
XII	308.90	308.90	308.90	308.90
XXIII	N.A	N.A	N.A	8,720.47
XIV	8.41	11.13	8.04	32.69
a)	8.41	11.13	8.04	32.69
b)	8.41	11.13	8.04	32.69

### Notes:

- The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Wednesday, 31st July, 2019. These results were subjected to Limited Review by the Statutory Auditors of the Company.
- The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
- The consolidated results are for NGL Fine Chem Limited together with its 100% subsidiary Macrochem Polychem Private Limited which was acquired by the company on 15th May 2019
- Previous period figures have been regrouped/rearranged wherever necessary.

Place: Mumbai  
Date: 31-Jul-19